← Back to Treatments
🏅 FDA Orphan Designation

Tegsedi

inotersen

Manufacturer: Ionis/AstraZeneca

Indicated for:
Hereditary ATTR amyloidosisOrphan

FDA-Approved Indications (1)

Hereditary ATTR amyloidosisOrphan Designation

Indicated for polyneuropathy of hATTR amyloidosis in adults.

Indications & Usage

Indicated for polyneuropathy of hATTR amyloidosis in adults.

💙 Support Programs

View all →
Tegsedi
Ionis/AstraZeneca
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.